(Boursier.com) — AB Science announced the publication in the peer-reviewed journal Journal of Asthma and Allergy of the results of its positive study of masitinib in the treatment of severe asthma not controlled by oral corticosteroids. AB Science explains that this phase 3 study (AB07015) evaluating masitinib administered orally at a dose of 6 mg/kg/day against placebo achieved its main objective: masitinib significantly reduced the number of severe exacerbations in patients with severe asthma not controlled by oral corticosteroids.
AB Science specifies in particular that a predefined subpopulation of patients suffering from severe asthma and having an elevated level of eosinophils also showed a statistically significant reduction in the rate of exacerbations of severe asthma by 38%. The benefit of masitinib was greatest in patients taking a higher cumulative dose of oral corticosteroids (a sign of more severe and more difficult to control asthma) with a statistically significant reduction in the rate of severe asthma exacerbations up to 71% for patients with a high eosinophil count taking a cumulative annual dose of oral corticosteroids greater than 1000 mg.
©2022 Boursier.com